Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535536 | 0.98 | HPGD (0.96) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5213430 | 0.96 | HPGD (0.93) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL14019821 | 0.93 | HPGD (0.87) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL20631562 | 0.92 | HPGD (0.86) | HPGDALDH1A1L3MBTL1KDM4EPOLB | |
| SCHEMBL31497563 | 0.89 | HPGD (0.79) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL2097647 | 0.86 | HPGD (0.74) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL28474010 | 0.86 | HPGD (0.75) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL10053023 | 0.86 | HPGD (0.75) | HPGDALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL7440364 | 0.84 | HPGD (0.73) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL9792247 | 0.84 | HPGD (0.79) | HPGDALDH1A1L3MBTL1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425733-A | CdS/ZnCr2O4Photocatalyst, preparation method and application thereof | 华南理工大学 | 2025-02-14 | — | — | CN | disclosed |
| EP-4359399-A1 | EP2 ANTAGONIST COMPOUNDS | Reservoir Neuroscience, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272062-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-109824465-B | Method for synthesizing amide by amine oxide catalyzed by bipyridine manganese catalyst | 陕西师范大学 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020070610-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LTD. (IN) | 2020-04-09 | — | — | WO | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HPGD 477/4885ALDH1A1 3756/4885L3MBTL1 3929/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | HPGD 345/4885ALDH1A1 2837/4885L3MBTL1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.